Treatment for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Research Site, Modesto, CA
COVID-19+1 More
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19

Eligible Conditions

  • COVID-19
  • Coronavirus Disease 2019 (COVID‑19)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for COVID-19

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: 2 years

15 months
Changes from baseline in GMTs and GMFRs values in SARS-CoV-2 nAbs
Incidence of ADA in serum
Serum AZD7442 concentrations
2 years
Adverse Events
Adverse Events of Special Interest
Serious Adverse Events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for COVID-19

Trial Design

0 Treatment Group

200 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Research Site · Modesto, CA
1900First Recorded Clinical Trial
30 TrialsResearching COVID-19
2948 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The consent form must be signed by the person who is considered by the Investigator to be legally unable to consent.
You are capable of giving informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
You are an adult or pediatric individual (≥ 18 years of age or ≥ 12 to < 18 years of age) weighing ≥ 40 kg at the time of signing the ICF or assent (for pediatric participants).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.